These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 15892670)

  • 1. Improving the targeting of tubulin-binding agents: lessons from drug resistance studies.
    Verrills NM; Kavallaris M
    Curr Pharm Des; 2005; 11(13):1719-33. PubMed ID: 15892670
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Microtubule alterations and resistance to tubulin-binding agents (review).
    Drukman S; Kavallaris M
    Int J Oncol; 2002 Sep; 21(3):621-8. PubMed ID: 12168109
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sensitivity of docetaxel-resistant MCF-7 breast cancer cells to microtubule-destabilizing agents including vinca alkaloids and colchicine-site binding agents.
    Wang RC; Chen X; Parissenti AM; Joy AA; Tuszynski J; Brindley DN; Wang Z
    PLoS One; 2017; 12(8):e0182400. PubMed ID: 28787019
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tubulin Proteins in Cancer Resistance: A Review.
    Kamal MA; Al-Zahrani MH; Khan SH; Khan MH; Al-Subhi HA; Kuerban A; Aslam M; Al-Abbasi FA; Anwar F
    Curr Drug Metab; 2020; 21(3):178-185. PubMed ID: 32101117
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The cytoskeleton as a therapeutic target in childhood acute leukemia: obstacles and opportunities.
    Liaw TY; Chang MH; Kavallaris M
    Curr Drug Targets; 2007 Jun; 8(6):739-49. PubMed ID: 17584029
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanisms of action of and resistance to antitubulin agents: microtubule dynamics, drug transport, and cell death.
    Dumontet C; Sikic BI
    J Clin Oncol; 1999 Mar; 17(3):1061-70. PubMed ID: 10071301
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Microtubule inhibitors: Differentiating tubulin-inhibiting agents based on mechanisms of action, clinical activity, and resistance.
    Perez EA
    Mol Cancer Ther; 2009 Aug; 8(8):2086-95. PubMed ID: 19671735
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting microtubules for cancer chemotherapy.
    Zhou J; Giannakakou P
    Curr Med Chem Anticancer Agents; 2005 Jan; 5(1):65-71. PubMed ID: 15720262
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Antitubulin agents].
    Dumontet C
    Bull Cancer; 2011 Nov; 98(11):1275-85. PubMed ID: 22023745
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DNA damage increases sensitivity to vinca alkaloids and decreases sensitivity to taxanes through p53-dependent repression of microtubule-associated protein 4.
    Zhang CC; Yang JM; Bash-Babula J; White E; Murphy M; Levine AJ; Hait WN
    Cancer Res; 1999 Aug; 59(15):3663-70. PubMed ID: 10446979
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tubulin and microtubules as targets for anticancer drugs.
    Hadfield JA; Ducki S; Hirst N; McGown AT
    Prog Cell Cycle Res; 2003; 5():309-25. PubMed ID: 14593726
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Taxanes with high potency inducing tubulin assembly overcome tumoural cell resistances.
    Matesanz R; Trigili C; Rodríguez-Salarichs J; Zanardi I; Pera B; Nogales A; Fang WS; Jímenez-Barbero J; Canales A; Barasoain I; Ojima I; Díaz JF
    Bioorg Med Chem; 2014 Sep; 22(18):5078-90. PubMed ID: 25047938
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Physiochemical aspects of tubulin-interacting antimitotic drugs.
    Correia JJ; Lobert S
    Curr Pharm Des; 2001 Sep; 7(13):1213-28. PubMed ID: 11472263
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanism of action of antitumor drugs that interact with microtubules and tubulin.
    Jordan MA
    Curr Med Chem Anticancer Agents; 2002 Jan; 2(1):1-17. PubMed ID: 12678749
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Microtubules: a dynamic target in cancer therapy.
    Pasquier E; Kavallaris M
    IUBMB Life; 2008 Mar; 60(3):165-70. PubMed ID: 18380008
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Microtubule Targeting Agents as Cancer Chemotherapeutics: An Overview of Molecular Hybrids as Stabilizing and Destabilizing Agents.
    Tangutur AD; Kumar D; Krishna KV; Kantevari S
    Curr Top Med Chem; 2017; 17(22):2523-2537. PubMed ID: 28056738
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HURP binding to the vinca domain of β-tubulin accounts for cancer drug resistance.
    Saju A; Chen PP; Weng TH; Tsai SY; Tanaka A; Tseng YT; Chang CC; Wang CH; Shimamoto Y; Hsia KC
    Nat Commun; 2024 Oct; 15(1):8844. PubMed ID: 39397030
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytoskeletal alterations that confer resistance to anti-tubulin chemotherapeutics.
    Kanakkanthara A; Teesdale-Spittle PH; Miller JH
    Anticancer Agents Med Chem; 2013 Jan; 13(1):147-58. PubMed ID: 22583426
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Microtubules and antineoplastic drugs].
    Arioka H; Saijo N
    Gan To Kagaku Ryoho; 1994 Apr; 21(5):583-90. PubMed ID: 7908790
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reference profiling of the genomic response induced by an antimicrotubule agent, TZT-1027 (Soblidotin), in vitro.
    Shimoyama T; Hamano T; Natsume T; Koizumi F; Kiura K; Tanimoto M; Nishio K
    Pharmacogenomics J; 2006; 6(6):388-96. PubMed ID: 16550209
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.